Zevra Therapeutics Inc. (ZVRA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Zevra Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Zevra Therapeutics Inc. (ZVRA) has returned 4.02% so far this year and 24.43% over the past 12 months. Over the last ten years, ZVRA has returned -27.88% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Apr 16, 2015, ZVRA's average daily return is +0.03%, while the average monthly return is +0.37%. At this rate, your investment would double in approximately 15.6 years.

Historically, 48% of months were positive and 52% were negative. The best month was Nov 2020 with a return of +77.2%, while the worst month was May 2016 at -57.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.

On a daily basis, ZVRA closed higher 46% of trading days. The best single day was Mar 3, 2021 with a return of +42.8%, while the worst single day was May 6, 2016 at -55.9%.

Zevra Therapeutics Inc. has an annualized alpha of -2.08%, beta of 0.83, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since April 17, 2015.

• This stock participated in 146.44% of S&P 500 Index downside but only -2.48% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ZVRA ranks 53 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Zevra Therapeutics Inc. (ZVRA) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Zevra Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Zevra Therapeutics Inc. was 99.27%, occurring on May 22, 2020. The portfolio has not yet recovered.

The current Zevra Therapeutics Inc. drawdown is 97.53%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Zevra Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Zevra Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.